In Brief: Medical device reporting
This article was originally published in The Gray Sheet
Medical device reporting: FDA stays effective date of certain portions of the annual baseline reporting requirement of the agency's December 1995 final manufacturer MDR rule. The stay, published in the July 31 Federal Register, applies to the number of devices manufactured, distributed or in use (so-called "denominator data"), which FDA had intended to use in determining the prevalence of adverse events. The agency is issuing the stay "until further notice" in response to device industry concerns about the provision. FDA will explore mechanisms for obtaining denominator data via a small-scale pilot project slated to begin this fall ("The Gray Sheet" July 15, p. 10). The remaining portions of the MDR rule became effective as scheduled July 31...
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.